Zhongxing Bio-Tech reports mixed 2024 amid industry headwinds

** Tianshui Zhongxing Bio-Technology (SZSE: 002772) reported a mixed financial performance for 2024, showcasing the complex dynamics facing the edible mushroom industry. While annual production increased by 7.36% to 356,700 tons, contributing to revenue of 1.933 billion yuan, the company's net profit attributable to shareholders decreased by 19.77% year-over-year to 128 million yuan, primarily due to lower prices for its golden needle mushrooms. To mitigate these challenges, Zhongxing Bio-Tech is optimizing production and focusing on high-margin products like *Hypsizygus marmoreus*.